Repair Biotechnologies is a preclinical biotechnology company focused on developing drugs for cholesterol and aging-related diseases. Our first-in-class Cholesterol Degrading Platform (CDP) technology is aimed at reversing atherosclerosis, familial hypercholesterolemias, and other conditions in which excess or modified cholesterol drives pathology.
Location: United States, New York, Syracuse
Employees: 1-10
Total raised: $2.15M
Founded date: 2018
Investors 5
| Date | Name | Website |
| - | Grapeseed.... | grapeseed.... |
| - | Longevityt... | longevityt... |
| - | Healthspan... | healthspan... |
| - | quadraScop... | quadrascop... |
| - | Bioverge | ventures.b... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 07.05.2019 | Seed | $2.15M | - |
Mentions in press and media 6
| Date | Title | Description |
| 08.05.2019 | Term Sheet — Wednesday, May 8 | THE $1 BILLION LOSS 2019 will be Lyft’s “peak loss year.” The ride-hailing giant has issued its first results as a public company, showing both strong growth and widening losses. Paid Content How can you protect what you can't see? From Ext... |
| 07.05.2019 | Repair Biotechnologies Grabs $2.15M Seed | SYRACUSE, NY, Repair Biotechnologies, Inc. announced today $2.15 million in seed venture funding. >> Click here for more funding data on Repair Biotechnologies >> To export Repair Biotechnologies funding data to PDF and Exce... |
| 07.05.2019 | Repair Biotechnologies Raises $2.15M Seed Round | SYRACUSE, N.Y.--(BUSINESS WIRE)--Repair Biotechnologies, Inc. announced today $2.15 million in seed venture funding, to accelerate the preclinical development of its pipeline of drugs targeting thymus regeneration, cancer, and atheroscleros... |
| 07.05.2019 | Repair Biotechnologies Secures $2.15M in Seed Funding | Repair Biotechnologies, Inc., a Syracuse, N.Y.-based biotechnology company, raised $2.15m in seed funding. The round was led by Jim Mellon, the billionaire investor and Chairman of Juvenescence Ltd, with participation from Emerging Longevit... |
| 07.05.2019 | Repair Biotechnologies Raises $2.15M Seed Round | SYRACUSE, N.Y.--(BUSINESS WIRE)--Repair Biotechnologies, Inc. announced today $2.15 million in seed venture funding, to accelerate the preclinical development of its pipeline of drugs targeting thymus regeneration, cancer, and atheroscleros... |
| - | Repair Biotechnologies | “Human cells cannot degrade cholesterol, leading to several chronic and orphan diseases. Repair Biotechnologies’ Cholesterol Degrading Platform (CDP) therapy solves this.” |